Credentialing for breast lymphatic mapping: How many cases are enough?

被引:116
作者
Cody, HS [1 ]
Hill, ADK [1 ]
Tran, KN [1 ]
Brennan, MF [1 ]
Borgen, PI [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
关键词
D O I
10.1097/00000658-199905000-00015
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To evaluate credentialing issues for sentinel lymphatic mapping for breast cancer. Summary Background Data The sentinel lymph node (SLN) is defined as the first lymph node receiving lymphatic drainage from a tumor. The SLN accurately reflects the status of the axillary nodes in patients with early-stage breast cancer, and SLN mapping is gaining widespread acceptance. Few of the many published feasibility studies of lymphatic mapping for breast cancer have adequate numbers to assess credentialing issues for this new procedure. Methods Five hundred consecutive SLN biopsies were performed at one institution, over a 20-month period, by eight surgeons, using isosulfan blue dye and technetium-labeled sulfur colloid. The authors reviewed each surgeon's success rate in finding the SLN, and false-negative rate, relative to level of experience with the technique. Results Lymphatic mapping performed by an experienced surgeon (surgeon A, B, or C) was associated with a higher success rate (94%) than when it was performed by one with less experience 86%. Ten failed mapping procedures occurred in the first 100 cases. For each of the ensuing 100 cases, there were eight, six, six, and four failed mapping procedures, suggesting that increasing experience does not eradicate failed mapping procedures completely. The false-negative rate among 104 patients in whom axillary dissection was planned in advance was 10.6% (5/47). Most false-negative results occurred early in the surgeon's experience: when the first six cases of every surgeon were excluded, the false-negative rate fell to 5.2%(2/38). Conclusions with increasing experience, failed SLN localizations and false-negative SLN biopsies occur less often. Combined dye and isotope localization, enhanced histopathology, a backup axillary dissection, and judicious case selection are required to avoid the high false-negative rate of one's early experience.
引用
收藏
页码:723 / 728
页数:6
相关论文
共 28 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]   Sentinel node biopsy in breast cancer [J].
Barnwell, JM ;
Arredondo, MA ;
Kollmorgen, D ;
Gibbs, JF ;
Lamonica, D ;
Carson, W ;
Zhang, P ;
Winston, J ;
Edge, SB .
ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (02) :126-130
[3]   CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].
BONADONNA, G ;
VALAGUSSA, P ;
MOLITERNI, A ;
ZAMBETTI, M ;
BRAMBILLA, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906
[4]   Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection [J].
Borgstein, P ;
Pijpers, R ;
Comans, EF ;
van Diest, PJ ;
Boom, RP ;
Meijer, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (03) :275-283
[5]   Intradermal blue dye to identify sentinel lymphnode in breast cancer [J].
Borgstein, PJ ;
Meijer, S ;
Pijpers, R .
LANCET, 1997, 349 (9066) :1668-1669
[6]  
CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO
[7]  
2-I
[8]  
Crossin JA, 1998, AM SURGEON, V64, P666
[9]   SURGICAL ADJUVANT CHEMOTHERAPY IN CANCER OF BREAST - RESULTS OF A DECADE OF COOPERATIVE INVESTIGATION [J].
FISHER, B ;
RAVDIN, RG ;
AUSMAN, RK ;
SLACK, NH ;
MOORE, GE ;
NOER, RJ .
ANNALS OF SURGERY, 1968, 168 (03) :337-+
[10]  
Flett MM, 1998, BRIT J SURG, V85, P991